256 Participants Needed

Vamikibart for Uveitic Macular Edema

(Sandcat Trial)

Recruiting at 152 trial locations
RS
Overseen ByReference Study ID Number: GR44278 https://forpatients.roche.com/
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.

Do I need to stop my current medications for the trial?

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have used certain eye treatments like IVT biologics, Methotrexate, or specific implants within a certain period before the trial starts.

Will I have to stop taking my current medications?

The trial does not specify if you must stop all current medications, but it does mention that certain eye treatments like specific injections or implants should not have been used recently. It's best to discuss your current medications with the trial team to see if they are allowed.

What data supports the idea that Vamikibart for Uveitic Macular Edema is an effective treatment?

The available research does not provide specific data on Vamikibart for Uveitic Macular Edema. Instead, it focuses on other treatments for different types of macular edema, such as aflibercept and pegaptanib, which are used for conditions like branch retinal vein occlusion. Without direct data on Vamikibart, we cannot conclude its effectiveness for Uveitic Macular Edema based on the provided information.12345

What safety data is available for Vamikibart (RO7200220) in treating uveitic macular edema?

The provided research does not contain any safety data for Vamikibart (RO7200220) or its other names (RG-6179, RO-7200220) in the treatment of uveitic macular edema. The studies focus on other treatments for macular edema, such as ranibizumab, aflibercept, conbercept, and fingolimod, but do not mention Vamikibart.36789

Is the drug Vamikibart a promising treatment for Uveitic Macular Edema?

The information provided does not directly mention Vamikibart or its effects on Uveitic Macular Edema. Therefore, we cannot determine if Vamikibart is a promising treatment for this condition based on the given research articles.510111213

Research Team

CT

Clinical Trials

Principal Investigator

Hoffmann-LaRoche

Eligibility Criteria

This trial is for women with uveitic macular edema, which causes swelling in the eye. They must have a certain level of vision impairment and agree to use contraception or abstain from sex. Those with recent major eye surgeries, infections like syphilis or tuberculosis, HIV, uncontrolled glaucoma, or who've used certain medications recently can't join.

Inclusion Criteria

I have swelling in the eye due to non-infectious inflammation.
BCVA letter score of 73 to 19 letters (inclusive) on Early Treatment Diabetic Retinopathy Study (EDTRS)-like charts
I agree to follow the study's rules on abstinence or contraception.
See 1 more

Exclusion Criteria

I have swelling in the back of my eye not caused by inflammation.
I have no eye conditions blocking the view or imaging of my retina.
I have a serious ongoing health or mental health condition.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 4 intravitreal injections every 4 weeks up to Week 12, followed by as-needed dosing from Week 20 to Week 48

48 weeks
4 visits (in-person) for initial injections, followed by PRN visits

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • RO7200220
Trial OverviewThe study tests Vamikibart's effectiveness and safety against uveitic macular edema compared to a sham treatment (placebo). Participants will be randomly assigned to receive either Vamikibart or the sham intervention to see if there's an improvement in their condition.
Participant Groups
3Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm BExperimental Treatment1 Intervention
Participants will receive 4 low-dose vamikibart IVT injections Q4W to Week 12, followed by PRN dosing from Week 20 to Week 48.
Group II: Arm AExperimental Treatment1 Intervention
Participants will receive 4 high-dose vamikibart intravitreal (IVT) injections every 4 weeks (Q4W) to Week 12, followed by as-needed (PRN) dosing from Week 20 to Week 48.
Group III: Arm CPlacebo Group1 Intervention
Participants will receive 4 sham injections Q4W to Week 12, followed by PRN sham dosing from Week 20 to Week 48.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway profile image

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker profile image

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University

Findings from Research

Intravitreal aflibercept (IVA) treatment for macular edema due to branch retinal vein occlusion (BRVO-ME) showed significant improvements in best corrected visual acuity and central foveal thickness over 24 months, with a remission rate of 87.5%.
Patients required fewer injections over time, averaging 2.2 injections in the first year and only 0.4 in the second year, suggesting that early treatment may help reduce the need for additional injections later on.
Twenty-four-month results of intravitreal aflibercept for macular edema due to branch retinal vein occlusion.Sakanishi, Y., Yasuda, K., Morita, S., et al.[2021]
In a study involving five patients with refractory macular edema due to branch retinal vein occlusion, treatment with intravitreal Pegaptanib sodium resulted in significant improvements in both visual acuity and macular edema after three months.
The findings suggest that Pegaptanib sodium is a safe and effective option for patients who do not respond to other treatments like bevacizumab or triamcinolone.
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion.Udaondo, P., Garcia-Delpech, S., Salom, D., et al.[2021]
In a phase III trial involving 183 treatment-naïve eyes with macular edema after branch retinal vein occlusion, intravitreal aflibercept injection (IAI) resulted in a significantly higher proportion of patients gaining 15 or more letters in visual acuity compared to macular grid laser treatment (52.7% vs. 26.7%).
IAI also led to a greater mean improvement in visual acuity (17.0 letters vs. 6.9 letters) and a more substantial reduction in central retinal thickness (280.5 μm vs. 128.0 μm) at 24 weeks, with minimal serious adverse events reported.
Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.Campochiaro, PA., Clark, WL., Boyer, DS., et al.[2022]

References

Twenty-four-month results of intravitreal aflibercept for macular edema due to branch retinal vein occlusion. [2021]
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion. [2021]
Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. [2022]
Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. [2022]
Dynamics of soluble vascular endothelial growth factor receptors and their ligands in aqueous humour during ranibizumab for age-related macular degeneration. [2022]
Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis). [2016]
Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab. [2020]
Comparison of intravitreal injection of conbercept and triamcinolone acetonide for macular edema secondary to branch retinal vein occlusion. [2020]
[Early onset of fingolimod-associated macular edema]. [2019]
BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale. [2023]
Aflibercept for the treatment of diabetic macular edema. [2022]
Effects of intravitreal injection of ranibizumab and aflibercept for branch retinal vein occlusion on the choroid: a retrospective study. [2022]
Aqueous soluble vascular endothelial growth factor receptor-2 in macular edema with branch retinal vein occlusion. [2013]